Alterations in Blood-Brain Barrier Permeability in Patients with Systemic Lupus Erythematosus

References

1. 1.↵
   2. Gulinello M,
   3. Wen J,
   4. Putterman C

   . Neuropsychiatric symptoms in lupus. Psychiatr Ann 2012;42:322–28 doi:10.3928/00485713-20120906-05 pmid:25620816

   CrossRefPubMed
2. 2.↵
   2. Rayes HA,
   3. Tani C,
   4. Kwan A, et al

   . What is the prevalence of cognitive impairment in lupus and which instruments are used to measure it? A systematic review and meta-analysis. Semin Arthritis Rheum 2018;48:240–55 doi:10.1016/j.semarthrit.2018.02.007 pmid:29571540

   CrossRefPubMed
3. 3.↵
   2. Calderón J,
   3. Flores P,
   4. Aguirre JM, et al

   . Impact of cognitive impairment, depression, disease activity, and disease damage on quality of life in women with systemic lupus erythematosus. Scand J Rheumatol 2017;46:273–80 doi:10.1080/03009742.2016.1206617 pmid:27701937

   CrossRefPubMed
4. 4.↵
   2. González A,
   3. Massardo L

   . Antibodies and the brain: antiribosomal P protein antibody and the clinical effects in patients with systemic lupus erythematosus. Curr Opin Neurol 2018;31:300–05 doi:10.1097/WCO.0000000000000549 pmid:29461425

   CrossRefPubMed
5. 5.↵
   2. Mader S,
   3. Brimberg L,
   4. Diamond B

   . The role of brain-reactive autoantibodies in brain pathology and cognitive impairment. Front Immunol 2017;8:1101 doi:10.3389/fimmu.2017.01101 pmid:28955334

   CrossRefPubMed
6. 6.↵
   2. Bravo-Zehnder M,
   3. Toledo EM,
   4. Segovia-Miranda F, et al

   . Anti-ribosomal P protein autoantibodies from patients with neuropsychiatric lupus impair memory in mice. Arthritis Rheumatol 2015;67:204–14 doi:10.1002/art.38900 pmid:25302407

   CrossRefPubMed
7. 7.↵
   2. Segovia-Miranda F,
   3. Serrano F,
   4. Dyrda A, et al

   . Pathogenicity of lupus anti-ribosomal P antibodies: role of cross-reacting neuronal surface P antigen in glutamatergic transmission and plasticity in a mouse model. Arthritis Rheumatol 2015;67:1598–610 doi:10.1002/art.39081 pmid:25709106

   CrossRefPubMed
8. 8.↵
   2. Chang EH,
   3. Volpe BT,
   4. Mackay M, et al

   . Selective impairment of spatial cognition caused by autoantibodies to the N-methyl-D-aspartate receptor. EBioMedicine 2015;2:755–64 doi:10.1016/j.ebiom.2015.05.027 pmid:26286205

   CrossRefPubMed
9. 9.↵
   2. Mackay M

   . Lupus brain fog: a biologic perspective on cognitive impairment, depression, and fatigue in systemic lupus erythematosus. Immunol Res 2015;63:26–37 doi:10.1007/s12026-015-8716-3 pmid:26481913

   CrossRefPubMed
10. 10.↵
    2. Lauvsnes MB,
    3. Beyer MK,
    4. Kvaløy JT, et al

    . Association of hippocampal atrophy with cerebrospinal fluid antibodies against the NR2 subtype of the N-methyl-D-aspartate receptor in patients with systemic lupus erythematosus and patients with primary Sjögren's syndrome. Arthritis Rheumatol 2014;66:3387–94 doi:10.1002/art.38852 pmid:25156222

    CrossRefPubMed
11. 11.↵
    2. Diamond B,
    3. Volpe BT

    . Antibodies and brain disease: a convergence of immunology and physiology. PLoS Med 2006;3:e498 doi:10.1371/journal.pmed.0030498 pmid:17177601

    CrossRefPubMed
12. 12.↵
    2. Sharp CD,
    3. Hines I,
    4. Houghton J, et al

    . Glutamate causes a loss in human cerebral endothelial barrier integrity through activation of NMDA receptor. Am J Physiol Heart Circ Physiol 2003;285:H2592–98 doi:10.1152/ajpheart.00520.2003 pmid:12893641

    CrossRefPubMedWeb of Science
13. 13.↵
    2. Fragoso-Loyo H,
    3. Cabiedes J,
    4. Orozco-Narváez A, et al

    . Serum and cerebrospinal fluid autoantibodies in patients with neuropsychiatric lupus erythematosus: implications for diagnosis and pathogenesis. PLoS One 2008;3:e3347 doi:10.1371/journal.pone.0003347 pmid:18836530

    CrossRefPubMed
14. 14.↵
    2. Arinuma Y,
    3. Yanagida T,
    4. Hirohata S

    . Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2008;58:1130–35 doi:10.1002/art.23399 pmid:18383393

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Gono T,
    3. Kawaguchi Y,
    4. Kaneko H, et al

    . Anti-NR2A antibody as a predictor for neuropsychiatric systemic lupus erythematosus. Rheumatology (Oxford) 2011;50:1578–85 doi:10.1093/rheumatology/keq408 pmid:21208977

    CrossRefPubMed
16. 16.↵
    2. Yoshio T,
    3. Onda K,
    4. Nara H, et al

    . Association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2006;54:675–78 doi:10.1002/art.21547 pmid:16447246

    CrossRefPubMedWeb of Science
17. 17.↵
    2. Gulati G,
    3. Jones JT,
    4. Lee G, et al

    . Altered blood-brain barrier permeability in patients with systemic lupus erythematosus: a novel imaging approach. Arthritis Care Res (Hoboken) 2017;69:299–305 doi:10.1002/acr.22923 pmid:27110957

    CrossRefPubMed
18. 18.↵
    2. Diamond B,
    3. Volpe BT

    . A model for lupus brain disease. Immuno Rev 2012;248:56–67 doi:10.1111/j.1600-065X.2012.01137.x pmid:22725954

    CrossRefPubMed
19. 19.↵
    2. Kowal C,
    3. Degiorgio LA,
    4. Lee JY, et al

    . Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci U S A 2006;103:19854–59 doi:10.1073/pnas.0608397104 pmid:17170137

    Abstract/FREE Full Text
20. 20.↵
    2. Latchaw R,
    3. Yonas H,
    4. Hunter G, et al

    ; Council on Cardiovascular Radiology of the American Heart Association. Guidelines and recommendations for perfusion imaging in cerebral ischemia: a scientific statement for healthcare professionals by the writing group on perfusion imaging, from the Council on Cardiovascular Radiology of the American Heart Association. Stroke 2003;34:1084–104 doi:10.1161/01.STR.0000064840.99271.9E pmid:12677088

    FREE Full Text
21. 21.↵
    2. Essig M,
    3. Shiroishi M,
    4. Nguyen T, et al

    . Perfusion MRI: the five most frequently asked technical questions. AJR Am J Roentgenol 2013;200:24–34 doi:10.2214/AJR.12.9543 pmid:23255738

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Heye AK,
    3. Culling RD,
    4. Valdés Hernández Mdel C, et al

    . Assessment of blood-brain barrier disruption using dynamic contrast-enhanced MRI: a systematic review. Neuroimage Clin 2014;6:262–74 doi:10.1016/j.nicl.2014.09.002 pmid:25379439

    CrossRefPubMed
23. 23.↵
    2. Ivanidze J,
    3. Kallas ON,
    4. Gupta A, et al

    . Application of blood-brain barrier permeability imaging in global cerebral edema. AJNR Am J Neuroradiol 2016;37:1599–603 doi:10.3174/ajnr.A4784 pmid:27127002

    Abstract/FREE Full Text
24. 24.↵
    2. Hartman EA,
    3. van Royen-Kerkhof A,
    4. Jacobs JW, et al

    . Performance of the 2012 Systemic Lupus International Collaborating Clinics classification criteria versus the 1997 American College of Rheumatology classification criteria in adult and juvenile systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev 2018;17:316–22 doi:10.1016/j.autrev.2018.01.007 pmid:29366725

    CrossRefPubMed
25. 25.↵
    2. Petri M,
    3. Kim MY,
    4. Kalunian KC, et al

    . Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550–58 doi:10.1056/NEJMoa051135 pmid:16354891

    CrossRefPubMedWeb of Science
26. 26.↵
    2. Gladman DD,
    3. Urowitz MB,
    4. Goldsmith CH, et al

    . The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:809–13 doi:10.1002/art.1780400506 pmid:9153540

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Roebuck-Spencer TM,
    3. Yarboro C,
    4. Nowak M, et al

    . Use of computerized assessment to predict neuropsychological functioning and emotional distress in patients with systemic lupus erythematosus. Arthritis Rheum 2006;55:434–41 doi:10.1002/art.21992 pmid:16739211

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Julian LJ,
    3. Tonner C,
    4. Yelin E, et al

    . Cardiovascular and disease-related predictors of depression in systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2011;63:542–49 doi:10.1002/acr.20426 pmid:21452266

    CrossRefPubMedWeb of Science
29. 29.↵
    2. Mackay M,
    3. Tang CC,
    4. Volpe BT, et al

    . Brain metabolism and autoantibody titres predict functional impairment in systemic lupus erythematosus. Lupus Sci Med 2015;2:e000074 doi:10.1136/lupus-2014-000074 pmid:25861456

    Abstract/FREE Full Text
30. 30.↵
    2. Hirohata S,
    3. Arinuma Y,
    4. Yanagida T, et al

    . Blood-brain barrier damages and intrathecal synthesis of anti-N-methyl-D-aspartate receptor NR2 antibodies in diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus. Arthritis Res Ther 2014;16:R77 doi:10.1186/ar4518 pmid:24655341

    CrossRefPubMed
31. 31.↵
    2. Tomkins O,
    3. Kaufer D,
    4. Korn A, et al

    . Frequent blood-brain barrier disruption in the human cerebral cortex. Cell Mol Neurobiol 2001;21:675–91 doi:10.1023/A:1015147920283 pmid:12043841

    CrossRefPubMedWeb of Science
32. 32.↵
    2. Wang P,
    3. Cagnoli P,
    4. McCune W, et al

    . Perfusion-weighted MR imaging in cerebral lupus erythematosus. Acad Radiol 2012;19:965–70 doi:10.1016/j.acra.2012.03.023 pmid:22608862

    CrossRefPubMed
33. 33.↵
    2. Gasparovic C,
    3. Roldan C,
    4. Sibbitt WL, et al

    . Elevated cerebral blood flow and volume in systemic lupus measured by dynamic susceptibility contrast magnetic resonance imaging. J Rheumatol 2010;37:1834–43 doi:10.3899/jrheum.091276 pmid:20551095

    Abstract/FREE Full Text
34. 34.↵
    2. Zimny A,
    3. Szmyrka-Kaczmarek M,
    4. Szewczyk P, et al

    . In vivo evaluation of brain damage in the course of systemic lupus erythematosus using magnetic resonance spectroscopy, perfusion-weighted and diffusion-tensor imaging. Lupus 2014;23:10–19 doi:10.1177/0961203313511556 pmid:24192079

    CrossRefPubMedWeb of Science
35. 35.↵
    2. Emmer B,
    3. van Osch M,
    4. Wu O, et al

    . Perfusion MRI in neuro-psychiatric systemic lupus erthemathosus. J Magn Reson Imaging 2010;32:283–88 doi:10.1002/jmri.22251 pmid:20677252

    CrossRefPubMed
36. 36.↵
    2. Danielski LG,
    3. Giustina AD,
    4. Badawy M, et al

    . Brain barrier breakdown as a cause and consequence of neuroinflammation in sepsis. Mol Neurobiol 2018;55:1045–53 doi:10.1007/s12035-016-0356-7 pmid:28092082

    CrossRefPubMed
37. 37.↵
    2. Reinhold AK,
    3. Rittner HL

    . Barrier function in the peripheral and central nervous system—a review. Pflugers Arch 2017;469:123–34 doi:10.1007/s00424-016-1920-8 pmid:27957611

    CrossRefPubMed